HeartSciences' Cash Boosted by $3.8M Offering Amidst Continued Losses

TL;DR

**HSCSW is burning cash but just got a $3.8M injection, so expect more volatility as they chase FDA approval for their AI-ECG.**

AI Summary

HeartSciences Inc. (HSCSW) reported a net loss of $2,054,994 for the three months ended July 31, 2025, a slight increase from the $2,051,689 net loss in the prior-year period. Revenue for the quarter was $1,900, up from zero in the same period last year, with a gross margin of $1,140. Operating expenses decreased to $1,875,259 from $2,075,667, primarily due to a reduction in research and development expenses from $1,224,931 to $997,206. The company's cash and cash equivalents significantly increased to $2,792,231 as of July 31, 2025, from $1,098,098 at April 30, 2025, largely driven by $3,796,376 in net proceeds from the issuance of Series D preferred stock and warrants. Despite this, the accumulated deficit grew to $78.2 million, up from $76.1 million, raising substantial doubt about its ability to continue as a going concern. The company is actively developing its MyoVista wav ECG device and MyoVista Insights Cloud Platform, preparing for U.S. FDA submissions.

Why It Matters

HeartSciences' ability to raise $3.8 million through Series D preferred stock and warrants is a critical lifeline, providing much-needed capital for its ongoing R&D efforts in AI-ECG technology. For investors, this indicates a continued belief in the company's long-term potential despite persistent losses and a 'going concern' warning. Employees and customers will watch for progress on FDA submissions for the MyoVista wav ECG and MyoVista Insights Cloud Platform, as successful regulatory clearance is essential for market entry and competitive positioning against larger medical device companies. The broader market will see this as a test case for early-stage medical technology firms reliant on capital raises to fund innovation.

Risk Assessment

Risk Level: high — The company has an accumulated deficit of $78.2 million as of July 31, 2025, and has incurred losses and negative cash flows from operations since inception, leading to a 'substantial doubt regarding the Company's ability to continue as a going concern.' While a recent $3.8 million capital raise provides a temporary buffer, the company's long-term viability hinges on successful FDA submissions and commercialization of its MyoVista wav ECG and MyoVista Insights Cloud Platform, which are uncertain.

Analyst Insight

Investors should approach HSCSW with extreme caution, recognizing it as a highly speculative investment. Monitor closely for updates on FDA submissions for the MyoVista wav ECG and MyoVista Insights Cloud Platform, as regulatory approval is the primary catalyst for potential value creation. Consider the significant dilution risk from ongoing capital raises, such as the $15.0 million ATM facility.

Financial Highlights

debt To Equity

N/A

revenue

$1,900

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$2,054,994

eps

-$1.58

gross Margin

60.0%

cash Position

$2,792,231

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $2.05M — Net Loss (Slight increase from $2.05M in prior year, indicating continued unprofitability.)
• $1,900 — Revenue (First reported revenue, up from zero, but still negligible.)
• $2.79M — Cash and Cash Equivalents (Significant increase from $1.10M at April 30, 2025, due to financing activities.)
• $78.2M — Accumulated Deficit (Increased from $76.1M, highlighting ongoing losses and 'going concern' risk.)
• $3.80M — Proceeds from Series D Offering (Key financing activity providing liquidity for operations.)
• 1-for-100 — Reverse Stock Split Ratio (Implemented May 17, 2024, to adjust share structure.)
• $997,206 — Research and Development Expenses (Decreased from $1,224,931, showing a reduction in R&D spend.)
• 1,317,689 — Series D Units Issued (Number of units issued in the recent offering.)
• $1.58 — Net Loss Per Share (Basic and diluted net loss per share for the quarter.)
• 2,647,712 — Common Stock Outstanding (Shares outstanding as of September 10, 2025.)

Key Players & Entities

• HeartSciences Inc. (company) — registrant
• U.S. Food and Drug Administration (regulator) — regulatory body for product approval
• Nasdaq Stock Market LLC (company) — exchange where securities are registered
• Lincoln Park Capital Fund, LLC (company) — institutional investor in Equity Distribution Agreement
• $2,054,994 (dollar_amount) — net loss for three months ended July 31, 2025
• $1,900 (dollar_amount) — revenue for three months ended July 31, 2025
• $78.2 million (dollar_amount) — accumulated deficit as of July 31, 2025
• $3,796,376 (dollar_amount) — net proceeds from Series D preferred stock and warrants
• $2,792,231 (dollar_amount) — cash and cash equivalents as of July 31, 2025
• $15.0 million (dollar_amount) — maximum offering amount for Series D Units

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's accumulated deficit grew to $78.2 million, and it reported a net loss of $2,054,994 for the three months ended July 31, 2025. This substantial deficit and ongoing losses raise substantial doubt about HeartSciences Inc.'s ability to continue as a going concern.
• FDA Approval Dependency [high — regulatory]: HeartSciences is actively developing its MyoVista wav ECG device and MyoVista Insights Cloud Platform, with preparations for U.S. FDA submissions underway. Delays or failure to obtain FDA approval would significantly hinder market entry and revenue generation.
• Limited Operating History [medium — operational]: The company has a limited operating history and has only recently begun generating revenue ($1,900 for the quarter). This lack of established market presence and operational track record presents a risk to future performance and scalability.
• Reliance on Financing [high — financial]: The significant increase in cash to $2,792,231 was primarily driven by $3,796,376 in net proceeds from the issuance of Series D preferred stock and warrants. The company remains reliant on future financing activities to fund its operations and development.
• Market Adoption Risk [medium — market]: Successful market adoption of the MyoVista wav ECG device and MyoVista Insights Cloud Platform is not guaranteed. Competition in the cardiac monitoring market is significant, and customer acceptance will be critical.

Industry Context

The cardiac monitoring market is characterized by technological advancements and increasing demand for remote patient monitoring solutions. Companies are focusing on developing more accurate, portable, and user-friendly devices. Key players compete on features, data analytics capabilities, regulatory approvals, and reimbursement strategies. HeartSciences aims to differentiate with its MyoVista wav ECG device and cloud platform.

Regulatory Implications

HeartSciences faces significant regulatory hurdles, primarily related to obtaining U.S. FDA approval for its MyoVista wav ECG device and MyoVista Insights Cloud Platform. Delays or failure in this process could severely impact market entry and commercial viability. Compliance with data privacy regulations (e.g., HIPAA) is also critical for the cloud platform.

What Investors Should Do

1. Monitor FDA Submission Progress
2. Assess Burn Rate and Future Financing Needs
3. Evaluate Market Adoption Post-Approval
4. Analyze R&D Spending Efficiency

Key Dates

• 2025-07-31: Quarter End — Reported $1,900 in revenue and a net loss of $2,054,994, with cash increasing to $2,792,231.
• 2025-04-30: Prior Quarter End — Cash and cash equivalents stood at $1,098,098 prior to the Series D financing.
• 2024-05-17: Reverse Stock Split — Implemented a 1-for-100 reverse stock split to adjust the common stock structure.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. It represents a negative balance in retained earnings. (A growing accumulated deficit, reaching $78.2 million, highlights the company's persistent unprofitability and contributes to going concern doubts.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If substantial doubt exists about a company's ability to continue as a going concern, it must be disclosed. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, a critical disclosure for investors.)

Series D Preferred Stock

A class of preferred stock, typically issued in later funding rounds (Series D), often with specific rights and preferences over earlier series and common stock. (The issuance of Series D preferred stock and warrants provided $3,796,376 in crucial funding, significantly boosting the company's cash position.)

Gross Margin

The difference between revenue and the cost of goods sold, expressed as a percentage of revenue. It indicates the profitability of a company's core product or service. (The reported gross margin of 60.0% ($1,140 revenue / $1,900 revenue) on minimal revenue suggests potential profitability on sales, but the scale is currently insignificant.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (HeartSciences implemented a 1-for-100 reverse stock split on May 17, 2024, likely to increase its per-share stock price and meet exchange listing requirements.)

Year-Over-Year Comparison

Compared to the prior-year period, HeartSciences Inc. has transitioned from zero revenue to reporting $1,900 in the current quarter, a positive albeit minuscule step. The net loss remained largely stable at approximately $2.05 million, indicating continued operational unprofitability. Operating expenses saw a reduction, primarily driven by decreased R&D spending from $1.22 million to $0.99 million. The most significant change is the substantial increase in cash reserves to $2.79 million, fueled by a recent equity financing round, which temporarily alleviates immediate liquidity concerns but does not resolve the underlying 'going concern' risk highlighted by the growing $78.2 million accumulated deficit.

Filing Documents

• hscs-20250731.htm (10-Q) — 1848KB
• hscs-ex31_1.htm (EX-31.1) — 17KB
• hscs-ex31_2.htm (EX-31.2) — 17KB
• hscs-ex32_1.htm (EX-32.1) — 10KB
• hscs-ex32_2.htm (EX-32.2) — 10KB
• 0001468492-25-000010.txt ( ) — 7806KB
• hscs-20250731.xsd (EX-101.SCH) — 1187KB
• hscs-20250731_htm.xml (XML) — 1190KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28 PART II. OTHER INFORMATION 29 Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30

Signatures

Signatures 34 i HEARTSCIENCES INC.

—FIN ANCIAL INFORMATION

PART I—FIN ANCIAL INFORMATION Ite m 1. Financial Statements. HeartSciences Inc. C ondensed Balance Sheets July 31, April 30, 2025 2025 (Unaudited) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 2,792,231 $ 1,098,098 Accounts receivable — 4,350 Inventory, net 649,507 650,267 Prepaid expenses 418,658 87,443 Deferred offering costs 515,825 290,925 Other current assets 40,374 40,374 Total current assets 4,416,595 2,171,457 Property and equipment, net 56,438 63,549 Intangible assets, net 1,617,091 1,616,277 Right-of-use assets, net 347,062 371,626 TOTAL ASSETS $ 6,437,186 $ 4,222,909 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 283,225 $ 318,661 Accrued expenses 599,287 506,307 Accrued interest expense 251,366 177,628 Operating lease liabilities, current portion 124,173 119,518 Notes payable 1,541,120 2,551,170 Other current liabilities 215,334 29,927 Total current liabilities 3,014,505 3,703,211 LONG-TERM LIABILITIES Operating lease liabilities, long-term 281,570 314,527 Total long-term liabilities 281,570 314,527 TOTAL LIABILITIES 3,296,075 4,017,738 COMMITMENTS AND CONTINGENCIES (NOTE 2, 4-6, and 8) STOCKHOLDERS' EQUITY Series C convertible preferred stock, $ 0.001 par value, 20,000,000 shares authorized and 600,000 designated; 380,440 shares issued and outstanding as of July 31, 2025 and April 30, 2025. 380 380 Series D convertible preferred stock, $ 0.001 par value, 20,000,000 shares authorized and 4,285,714 designated; 429,901 shares issued and outstanding as of July 31, 2025 and 0 shares issued and outstanding at April 30, 2025. 430 — Common stock, $ 0.001 par value, 500,000,000 shares authorized; 2,281,054 shares issued and outstanding as of July 31, 2025 and 1,119,107 shares issued and outstanding as of April 30, 2025. 2,281 1,119 Additional p

View Full Filing

View this 10-Q filing on SEC EDGAR